What is TRELEGY?
TRELEGY is a prescription medication that is designed to help manage chronic obstructive pulmonary disease (COPD). This medication is a combination of three different active ingredients: fluticasone furoate, umeclidinium, and vilanterol.
Fluticasone furoate is a corticosteroid that works to help reduce inflammation in the airways. It is often used in the treatment of asthma and COPD. Umeclidinium is an anticholinergic medication that helps to relax the muscles in the airways, making it easier to breathe. And vilanterol is a long-acting beta-agonist that helps to open up the airways, making it easier to breathe and reducing episodes of shortness of breath.
TRELEGY is typically administered via an inhaler and is taken once daily. It is important to use this medication as directed by your healthcare provider.
Some of the common side effects of TRELEGY can include headache, cough, lower respiratory tract infection, and thrush (a fungal infection in the mouth and throat). These side effects are usually mild and go away on their own, but if you experience any unusual symptoms or reactions, you should contact your healthcare provider right away.
Overall, TRELEGY is a well-tolerated medication that can help to improve lung function and quality of life in people with COPD. It is important to always consult with a healthcare provider to ensure proper use and management of this medication.
Frequently Asked Questions about trelegy
Once-daily TRELEGY is a prescription medicine used long term to treat COPD, including chronic bronchitis, emphysema, or both and to treat asthma in adults. TRELEGY 100/62.5/25 mcg is the only strength approved for COPD.
Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.
TRELEGY combines 3 long-acting medicines in 1 inhaler. That means 1 single inhalation once a day gives you a full 24 hours of better breathing. Your results may vary. Do not stop taking TRELEGY unless told to do so by your healthcare provider because your symptoms might get worse.
All three ingredients are produced at GSK's plant in Jurong, Singapore.
Trelegy Ellipta can only be obtained with a prescription. It is available as an inhalation powder, which the patient inhales through the mouth using a portable inhaler device; the patient should inhale the medicine once a day at around the same time each day.
TRELEGY contains an inhaled corticosteroid (ICS), an anticholinergic, and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems. Do not use TRELEGY to relieve sudden breathing problems.
GSK
Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®, which were jointly developed by Innoviva and GSK.
Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators.
Trelegy contains fluticasone, vilanterol and umeclidinium, while Breo contains only fluticasone and vilanterol. Because Trelegy contains an extra medicine, some side effects may differ between the two drugs.
TRELEGY is the first and only once-daily triple therapy in a single inhaler for asthma. This means that 3 medicines work together to help you breathe better by preventing and controlling asthma symptoms for a full 24 hours, all day and all night. TRELEGY also helps improve lung function.
Trelegy Ellipta is a brand-name prescription medication. It's FDA-approved for the long-term maintenance treatment of: chronic obstructive pulmonary disease (COPD), which is a group of lung conditions that include emphysema and chronic bronchitis. asthma.
TRELEGY FOR ASTHMA: annualized rate of exacerbations
The mean annualized rate of exacerbations was 0.31 for both TRELEGY (100 and 200; n=814) and for BREO (100 and 200; n=813), with a 2.6% reduction in rate (95% CI: -26.2, 24.9) with TRELEGY compared with BREO.
